Quantcast

Latest HUMIRA Stories

2008-12-01 07:00:00

Increased Uptake of Current Agents and Emergence of New Therapies Will Drive Robust Annual Market Growth, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Abbott/Eisai's Humira is poised to overtake Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade as the Crohn's disease market leader by 2012. Humira will retain its...

2008-10-22 09:00:41

Abbott Laboratories has reported new positive data from the company's CHARM and CHOICE trials of Humira, a fully human monoclonal antibody approved for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn's disease and juvenile idiopathic arthritis in the US and Europe. The data showed that Humira provided long-term treatment of fistulas, with more than half of patients with moderate to severe Crohn's disease experiencing fistula healing at...

2008-10-06 12:00:43

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success http://www.reportlinker.com/p095770/Commercial-Insight-Inflammatory-Bowel-Disease---Convenience-and-compliance-drive-market-success.html Introduction Several product launches and indication expansion caused substantial sales growth in the seven major...

2008-09-19 12:00:35

Abbott has announced new positive data from a sub-analysis of the company's pivotal, 52-week study, Reveal, which demonstrated that more psoriasis patients achieve efficacy when they receive continuous treatment with Humira compared to patients who interrupt their therapy. The sub-group analysis was designed to determine whether interrupting Humira treatment would affect efficacy in psoriasis patients who had already achieved good response to Humira. After 33 weeks, patients who had...

2008-09-18 09:00:50

WALTHAM, Mass., Sept. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 77 percent of surveyed dermatologists name Amgen/Wyeth/Takeda's Enbrel as their preferred first-line biologic therapy. The critical factors driving surveyed dermatologists' use of Enbrel ahead of Abbott/Eisai's Humira are its perceived better side-effect/safety profile and wealth of long-term safety data, as well as...

2008-09-18 06:00:22

PARIS, Sept. 18 /PRNewswire-FirstCall/ -- More psoriasis patients achieve efficacy when they receive continuous treatment with HUMIRA(R) (adalimumab) compared to patients who interrupt their therapy, according to data presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris. The findings were from a sub-analysis of Abbott's pivotal, 52-week study, REVEAL (The Randomized Controlled EValuation of Adalimumab Every Other Week in Moderate to Severe Psoriasis...

f1c5603c4629abec890a8b690b75b412
2008-09-05 09:45:00

The Food and Drug Administration warned yesterday that a handful of medications commonly prescribed to treat rheumatoid arthritis and other serious illnesses can raise the risk of fatal fungal infections. The drugs are called Enbrel, Remicade, Humira and Cimzia. They treat arthritis by suppressing the immune system to keep it from attacking the body. The treatment provides relief from swollen and painful joints, but it's "a double-edged sword," said the FDA's Dr. Jeffrey Siegel. That's...

2008-08-13 09:01:16

WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual five percent growth through 2017 in the ulcerative colitis drug market will be driven by strong uptake of Abbott/Eisai's Humira, Centocor/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's golimumab and Bristol-Myers Squibb's Orencia, following the expected approvals and launches of these three biologic agents...

2008-01-18 18:00:11

ABBOTT PARK, Ill., Jan. 18 /PRNewswire-FirstCall/ -- Abbott announced today it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment for adult patients with moderate to severe chronic plaque psoriasis, an autoimmune disease characterized by skin lesions that are sometimes painful and itchy. HUMIRA has been approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic...

2007-10-22 12:00:12

ABBOTT PARK, Ill., Oct. 22 /PRNewswire-FirstCall/ -- Abbott has received a 2007 Chicago Innovation Award for its m2000(TM) molecular diagnostic instrument (http://www.abbott.com/global/url/content/en_US/60.15:15/feature/Feature_0021.htm ) and the Abbott RealTime HIV-1 viral load test, the most sensitive test of its kind capable of detecting and precisely measuring all known strains of the human immunodeficiency virus (HIV). Abbott's RealTime HIV-1 test, approved for use in the United...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related